已收盘 09-12 16:00:00 美东时间
-3.070
-3.56%
Stifel resumed its coverage of cancer drug developer Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy recommendation and a $44 price target, citing commercial prospects of its newly launched medicines,...
09-11 00:12
今日重点评级关注:Canaccord Genuity:维持Aris Mining"买入"评级,目标价从16.5美元升至17美元;花旗:维持Docusign"买入"评级,目标价从110美元升至115美元
09-05 09:40
B of A Securities analyst Tazeen Ahmad maintains Incyte (NASDAQ:INCY) with a Buy and raises the price target from $90 to $104.
09-05 02:01
Over the past decade, 22 stocks in the S&P 500 have posted negative total returns, according to data compiled by the Bespoke Investment Group, indicating that long-term underperformance is quite rare ...
08-26 17:18
Across the recent three months, 13 analysts have shared their insights on Incyt...
08-23 02:02
JP Morgan analyst Jessica Fye maintains Incyte (NASDAQ:INCY) with a Neutral and raises the price target from $67 to $73.
08-22 22:17
Incyte Corporation (($CC:INCY.CUR)) announced an update on their ongoing clinic...
08-22 00:04
Evercore ISI分析师表示,医疗保健板块近期显现初步复苏信号。此前,该板块相对于标普500指数的估值折价幅度创下30年来新高。
08-20 08:56
The health care sector (NYSEARCA:XLV) is showing early signs of recovery after experiencing its largest valuation discount to the S&P 500 (SP500) in 30 years, according to Evercore ISI analysts. Since...
08-20 03:48